shortagewatch

Home / Cancer and immune system / Afatinib

ATC L01EB03 · Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors

Afatinib shortage

As of 2 Nov 2026, Afatinib has a reported shortage in 1 of the 16 countries we track (Canada), covering 9 products from 2 companies.

Countries1/16
Products9packs or presentations
Companies21 listed
Short since3 Aug 20263 months ago
Earliest return4 Dec 2026company estimate
Main reasonOther
United StatesNo reported shortageCanada9 products shortGermanyNo reported shortageFranceNo reported shortageItalyNo reported shortageSpainNo reported shortageIrelandNo reported shortageAustriaNo reported shortageBelgiumNo reported shortageSwitzerlandNo reported shortageCzechiaNo reported shortageNorwayNo reported shortageSwedenNo reported shortageJapanNo reported shortageNew ZealandNo reported shortageAustraliaNo reported shortage

Timeline

Canada
2027SANDOZ AFATINIB (30FCT)SANDOZ AFATINIB (30FCT)SANDOZ AFATINIB (30 FCT)SANDOZ AFATINIB (30 FCT)SANDOZ AFATINIB (30FCT)SANDOZ AFATINIB (30FCT)today

Solid bars run from the reported start to today; faded bars show the time left until the expected return. An arrow means no return date was given.

Which companies are short

products short, all countries
Boehringer Ingelheim6Sandoz3 SDZ

Listed: Sandoz SDZ · SIX Swiss

Compared with similar medicines

ATC group L01EB · Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
Erlotinib5/16Gefitinib2/16Afatinib1/16Dacomitinib1/16

Affected products

CountryProductCompanySinceExpected backReason
CASANDOZ AFATINIB (30FCT)SANDOZ CANADA INCORPORATED3 Aug 20264 Dec 2026Manufacturing problem
Disruption of the manufacture of the drug
CASANDOZ AFATINIB (30 FCT)SANDOZ CANADA INCORPORATED14 Sep 20264 Dec 2026Active ingredient shortage
Shortage of an active ingredient
CASANDOZ AFATINIB (30FCT)SANDOZ CANADA INCORPORATED14 Sep 20264 Dec 2026Active ingredient shortage
Shortage of an active ingredient
CAGIOTRIF (4x28) anticipated discontinuationBOEHRINGER INGELHEIM (CANADA) LTD LTEE31 Jan 202731 Jan 2027Other
Other (Please describe in comments)
CAGIOTRIF (4x7) anticipated discontinuationBOEHRINGER INGELHEIM (CANADA) LTD LTEE31 Jan 202731 Jan 2027Other
Other (Please describe in comments)
CAGIOTRIF (4x7) anticipated discontinuationBOEHRINGER INGELHEIM (CANADA) LTD LTEE31 Jan 202731 Jan 2027Other
Other (Please describe in comments)
CAGIOTRIF (4x28) discontinuationBOEHRINGER INGELHEIM (CANADA) LTD LTEEnot given31 Jan 2027Not stated
CAGIOTRIF (4x28) discontinuationBOEHRINGER INGELHEIM (CANADA) LTD LTEEnot given31 Jan 2027Not stated
CAGIOTRIF (4x28) discontinuationBOEHRINGER INGELHEIM (CANADA) LTD LTEEnot given31 Jan 2027Not stated

"Expected back" is the date the company gave the authority, when it gave one. Ask a pharmacist about alternatives.